Factors Influencing Second-Line Treatment with Triplet Therapy for Patients with RRMM in Routine Care
This study assessed factors that influenced the use of 3-drug combination therapy as a second-line treatment choice in patients with relapsed/refractory multiple myeloma (RRMM) who were managed in routine care.
In this study, the clinical value of minimal residual disease (MRD) status in achieving prolonged remissions was assessed in patients with multiple myeloma (MM) who had achieved at least very good partial response or complete response at 4 to 8 months and 12 to 24 months, or long-term relapse-free survivors (>6 years).
A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting.
Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM).
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events.
ISS Staging May Be Inadequate in Classifying All Patients with Newly Diagnosed MM by Disease and Symptom Burden
This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM).
Bortezomib-Based Induction and Maintenance Therapy Results in Durable Survival Improvements in Newly Diagnosed MM Patients
Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported.
Clinical Benefit of Bortezomib/Melphalan/Prednisone Followed by Lenalidomide/Dexamethasone in Elderly Newly Diagnosed Patients with MM
To further optimize therapy, this study identified subgroups that benefited least from bortezomib/melphalan/prednisone followed by lenalidomide/dexamethasone regimen in newly diagnosed patients aged 65 to 80 years with multiple myeloma (MM) included in the GEM2010 trial.
Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study
Daratumumab in combination with pomalidomide and dexamethasone is being evaluated in a 4-arm, multicenter, phase 1b study in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Initial findings show deep and durable responses, a high response rate, and good tolerability.
Page 16 of 18
Results 151 - 160 of 179
Results 151 - 160 of 179